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Primary carnitine deﬁciency (PCD) is an autosomal recessive
disorder of fatty-acid oxidation caused by deﬁciency in the plasma
membrane carnitine transporter. Carnitine plays an essential part in
the transfer of long-chain fatty acids across the inner mitochondrial
membrane. Carnitine deﬁciency blocks the mitochondrial oxidation of
fatty acids to carbon dioxide, and can result in acute metabolic
decompensation with hepatic encephalopathy, hypoketotic hypoglyce-
mia or, in a more insidious presentation, cardiomyopathy [1]. Cardio-
myopathy associated with PCD often presents with life-threatening
heart failure. Early recognition of this disorder and treatment with
carnitine can save lives. Here, we discuss the clinical features,
echocardiographic features, and treatment of PCD cardiomyopathy.
Six patients with PCD cardiomyopathy were diagnosed in our
hospital between January 2012 and December 2013 (Table 1, Figs. 1 and
2). In these 6 patients, there were no episodes of hypoketotic
hypoglycemia. The main manifestations were cardiac dilatation and
cardiac insufﬁciency. Case 3 had no obvious symptoms and was
diagnosed by screening because she was the sister of Patient 2.
Blood levels of glucose, creatinine, blood urea nitrogen, alanine
transaminase, aspartate aminotransferase, hemobilirubin, lactic acid,
amino acids, creatine kinase (CK), CK-MB, and CK-MM were normal,
as was the level of urinary ketones. Chest radiography revealed
cardiomegaly. Electrocardiography (ECG) in 2 patients showed high and
sharp T waves. In the 6 patients, echocardiography demonstrated
enlargement of the left ventricle that was coexistent with myocar-
dial thickening as well as with thickening of the trabecular and
mitral valve papillary muscles (Table 2). Left ventricular ejection
fraction (LVEF) was strikingly reduced in all cases except for Patient
3. The mean value of the serum carnitine level of the 6 patients was
1.37 ± 0.66 μmol/L (reference range, 10–60 μmol/L) at the time of
the diagnosis. High-throughput sequencing revealed that all cases
had mutations in the SLC22A5 gene.
After conﬁrmation of the diagnosis, all patients underwent treat-
ment with L-carnitine supplements (200–300 mg/day, p.o.) plus
digoxin, diuretics, and vasodilators. A follow-up study was available in
all 6 patients at a median of 11 months (range, 4 months to 2 years).
This treatment resulted in the disappearance of symptoms. Left
ventricular (LV) function returned to normal b1 month after carnitine
supplementation. Also, the heart size decreased to normal within a few
months of therapy.
Aconsiderablybroadphenotypic range is associatedwithPCD, ranging
fromearly infantile decompensation to adultswhoare asymptomatic. The
most common presentation of the disease is progressive cardiomyopathy
with or without weakness in skeletal muscles [2]. The average age for the
presentation of cardiomyopathy is 2–4 years. More than half of the
reported cases of PCD ﬁrst present between 12 months to 7 years of age
with progressive heart failure. This ﬁnding suggests that the manifesta-
tions of severe carnitinedeﬁciency in theheart and skeletalmuscles take a
long time to appear [2,3].
Studies have shown that the echocardiographic ﬁndings of PCD
cardiomyopathy are usually non-speciﬁc. Some patients have the
characteristics of dilated cardiomyopathy and some have the features of
hypertrophic cardiomyopathy [4–7]. However, the present study revealed
that the echocardiographic characteristics of PCD cardiomyopathy are
different to dilated cardiomyopathy or hypertrophic cardiomyopathy. LV
enlargement with decreased LVEF, coexistent with myocardial thickening
as well as with thickening of the trabecular and mitral valve papillary
muscles, are special characteristics of PCD cardiomyopathy. Interventri-
cular septal and ventricular walls were clearly hypertrophic, but the
degree of thickening was less than that for cases with hypertrophic
cardiomyopathy, andobstructionof the LVoutﬂowtractwasnotobserved.
Papillary muscles and the tendinous cords of the mitral valve and
trabeculae were also hypertrophic. Actually, based on the diagnostic
experience of theﬁrst 4 patients in this study, Patient 5 and Patient 6were
suspected of having PCD solely on their echocardiographic characteristics,
and subsequent tests conﬁrmed our initial suspicion. Patient 3 was
asymptomatic and echocardiography showed slight LV enlargement with
normal LV function, but Patient 3 presented with obvious ventricular
hypertrophy.Thisﬁndingmaysuggest that, becauseof carnitinedeﬁciency
and defective oxidation of fatty acids, fats accumulate in heart muscle,
resulting in ventricular hypertrophy in the initial phase. Then, as the
disease progresses, the left ventricle becomes impaired and dilated.
The key to the diagnosis is measurement of plasma carnitine
levels, which are extremely reduced (free carnitine b5 μmol/L;
controls 10–60 μmol/L) [1,5]. In the present study, plasma levels of
free carnitine were b5 μmol/L for all patients. PCD can be conﬁrmed
by mutation analyses of the SLC22A5 gene. PCD has been proven to
be an autosomal recessive disorder, and DNA studies have found
heterogeneous mutations in different patients [8]. Our patients
displayed homozygosity or compound heterozygosity for SLC22A5
gene mutations. Until now, the association between genotype and
phenotype in PCD was not clear.
Cardiac function responds poorly to treatment with diuretics and
digoxin in PCD patients. Continued therapy with L-carnitine supple-
ments can lead to dramatic resolution of severe congestive heart
failure within a short period, thereby altering the natural history of
the disease and reducing (or eliminating) the signs of cardiomyo-
pathy [2]. The Food and Drug Administration in the USA ﬁrst
approved L-carnitine in 1985 for the treatment of PCD. Intravenous
therapy with carnitine at 100–400 mg/kg per day is recommended
during life-threatening events, whereas carnitine at 100–300 mg/kg
per day given via the oral route is recommended for chronic cases [3].
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Our study revealed that oral treatment with L-carnitine was quite
effective against PCD cardiomyopathy. One study in patients with
PCD cardiomyopathy suggested that long-term carnitine supplemen-
tation can normalize cardiac function for N30 years, showing that
supplementation therapy can allow PCD patients to lead a normal life
[6].
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Fig. 1. Images for Patient 4. A: Transthoracic echocardiogram before carnitine
supplementation showing myocardial thickening, left ventricular enlargement and
pericardial effusion. B: Echocardiogram before carnitine supplementation. Arrow shows
thickened papillary muscle. C: Two weeks after carnitine therapy. The left ventricle has
decreased in size and pericardial effusion has disappeared. D: One month after therapy.
Heart size has reduced to normal with mild myocardial hypertrophy. E: SLC22A5 high-
throughput sequencing of the blood of the family. Gene sequences of Patient (1) show that
he has a homozygote of the c.338GNAmutation. Gene sequences of the patient's father (2)
andmother (3) show a heterozygote of the c.338GNAmutation. LV, left ventricle; RV, right
ventricle; LA, left atrium; RA, right atrium; and IVS, interventricular septum.
Table 1
Clinical characteristics, free carnitine levels, and SLC22A5 gene-sequencing results.
Case no. Sex Age (y) Main symptom Deceased sibling Free carnitine level (μmol/L) SLC22A5 gene sequencing
Allele 1 Allele 2
1 F 1.5 Dyspnea, pale complexion + 0.69 c.760CNT, p.R254X c.865CNT, p.R289C
2 M 6 Apocleisis, dyspnea − 0.50 c.338GNA, p.C113Y c.760CNT, p.R254X
3 F 0.5 Asymptomatic − 0.55 c.338GNA, p.C113Y c.760CNT, p.R254X
4 M 1 Dyspnea, hyperhidrosis + 4.58 c.760CNT, p.R254X c.760CNT, p.R254X
5 M 14 Dyspnea, weakness − 1.40 c.338GNA, p.C113Y c.760CNT, p.R254X
6 M 1 Dyspnea, growth retardation − 0.49 c.338GNA, p.C113Y c.338GNA, p.C113Y
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Fig. 2. Images for Patient 5. A: Echocardiogram before therapy. Myocardial thickening, left ventricular enlargement andmitral regurgitation is observed. B: Echocardiogram 3 months
after L-carnitine treatment shows a left ventricle reduced in size and no mitral regurgitation. C: SLC22A5 gene sequences of the blood of the family. Gene sequences of Patient (1)
show that compound heterozygosity for c.338GNA and c.760CNT mutations. His father (2) has a heterozygote of the c.760CNT mutation and his mother (3) has a heterozygote of the
c.338GNA mutation. LV, left ventricle; RV, right ventricle; LA, left atrium; and RA, right atrium.
Table 2
Echocardiographic parameters before and after L-carnitine supplementation⁎.
Case
no.
LVDd (mm) LVEF (%) IVSd (mm) LVPWd (mm) RVAWd (mm)
Before After Before After Before After Before After Before After
1 46.70 28.00 37 64 6.50 6.20 6.70 6.90 6.0 5.8
2 51.00 39.00 24 74 10.60 8.70 11.5 7.20 6.90 6.20
3 32.00 28.00 62 73 8.20 7.20 7.60 6.40 7.10 5.80
4 45.20 33.00 39 75 11.70 11.00 8.80 8.50 8.10 7.50
5 60.40 45.00 33 64 17.50 15.00 16.60 12.00 11.00 8.6
6 40.80 31.00 32 66 8.30 6.30 9.30 7.60 7.50 6.30
⁎ LVDd, left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; IVSd, interventricular septum diameter; LVPWd, left ventricular posterior wall diameter; RVAWd,
right ventricular anterior wall diameter.
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